Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1697850

	registered interest
	date	21/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Genetics: Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many patients in the South West have been eligible for pre-implantation genetic testing for monogenic disorders in each of the last five years.
	tabling member constituency	Bristol East
	tabling member printed	Kerry McCarthy
	uin	19828
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>Pre-implantation Genetic Testing (PGT) is used to identify genetic anomalies in embryos created through in-vitro fertilisation. Over 600 genetic conditions can currently be tested for using this technique, as licensed by the Human Fertilisation and Embryology Authority. NHS England has commissioned five centres to provide PGT to patients in England. The number of PGT cycles undertaken has increased from 223 patients in 2009 to 620 in 2019, but NHS England does not have access to data that describes the geographical profile of the people that have used the National Health Service or privately commissioned PGT services.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 10:39:37 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1491 label Biography information for Kerry McCarthy

1698562

	registered interest
	date	25/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much funding her Department has provided for research and development into a (a) cure and (b) vaccine for HIV in each year since 2019.
	tabling member constituency	Vauxhall
	tabling member printed	Florence Eshalomi
	uin	20480
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Department supports research on the human immunodeficiency virus (HIV) through the National Institute for Health and Care Research (NIHR). The remit of the NIHR is translational, clinical, and applied healthcare research. Basic research towards the development of a novel cure or vaccine for HIV is supported by other research funders such as the Medical Research Council. The NIHR has awarded over £10 million of funding since 2019 for research to evaluate new HIV treatments. The below table shoes the specific NIHR spend on HIV treatments, for each financial year since 2019:</p><table><tbody><tr><td><p>Year</p></td><td><p>2019/20</p></td><td><p>2020/21</p></td><td><p>2021/22</p></td><td><p>2022/23</p></td><td><p>2023/24</p></td><td><p>Total</p></td></tr><tr><td><p>NIHR spend</p></td><td><p>£3,260,413</p></td><td><p>£1,884,962</p></td><td><p>£1,299,676</p></td><td><p>£2,377,284</p></td><td><p>£1,209,822</p></td><td><p>£10,032,156</p></td></tr></tbody></table> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 10:41:29 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4870 label Biography information for Florence Eshalomi

1698563

	registered interest
	date	25/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much funding her Department plans to provide for research and development into HIV in the (a) 2024-25 and (b) 2025-26 financial year.
	tabling member constituency	Vauxhall
	tabling member printed	Florence Eshalomi
	uin	20481
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Department supports research and development on the human immunodeficiency virus (HIV) through the National Institute for Health and Care Research (NIHR). For the financial years 2024/25 and 2025/26, the Government has committed to a new £20 million research project to evaluate an expansion of HIV opt-out testing, in 47 emergency departments in England where HIV prevalence is high.</p><p>However, NIHR funding awarded for HIV projects varies depending on the volume and quality of applications received and approved via open competition, which means overall NIHR funding for HIV research in the financial years 2024/25 and 2025/26 is not yet known. The NIHR welcomes funding applications for research into any aspect of human health, including HIV.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 10:44:38 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4870 label Biography information for Florence Eshalomi

1698602

	registered interest
	date	25/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mental Health Services: Stockport
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent steps she has taken to help reduce waiting times for child and adolescent mental health services in Stockport constituency.
	tabling member constituency	Stockport
	tabling member printed	Navendu Mishra
	uin	20454
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>We want to ensure that children and young people get the mental health support they need, including in the Stockport constituency, and overall spending on mental health has increased by more than £4.7 billion in cash terms since 2018/19. This has enabled an expansion of child and young people's mental health services. As of January 2024, the latest data from NHS Digital shows there were 758,485 children and young people aged under 18 years old, supported through National Health Service funded mental health services with at least one contact.</p><p>We have introduced two waiting-time standards for children and young people. The first is for 95% of children, up to 19 years old, with eating disorders to receive treatment within one week for urgent cases, and four weeks for routine cases. The second is for 50% of patients of all ages experiencing a first episode of psychosis to receive treatment within two weeks of referral.</p><p>NHS England is developing a new waiting time measure for children and their families and carers to start to receive community-based mental health care within four weeks from referral. NHS England began publishing this new data in 2023 to improve transparency and drive local accountability.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 16/04/2024 14:51:23 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4811 label Biography information for Navendu Mishra

1699135

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Social Services: Supported Housing
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of variations in access to appropriate social care provision to enable independent living on the (a) availability and (b) capacity of supported accommodation.
	tabling member constituency	Nottingham East
	tabling member printed	Nadia Whittome
	uin	20822
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>Our white paper People at the Heart of Care sets out our ambition to ensure people have the choice and control to remain independent in the community. We recognise that supported housing can be the best model of care for some people, leading to better health, greater independence, and closer connection with the community.</p><p>The forthcoming provisions of the Supported Housing (Regulatory Oversight) Act 2023 will strengthen the data on the availability and capacity of supported accommodation. The act places a new duty on local housing authorities to review the supported housing in each district, and to forecast future need. The Government will consult on the implementation of the new duties and other supported housing reforms in due course.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 16/04/2024 10:51:14 answering member 4527 label Biography information for Helen Whately
	tabling member	4869 label Biography information for Nadia Whittome

1700034

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the adequacy of the reasons the (a) National Institute for Health and Care Excellence has been unable and (b) Scottish Medicines Consortium has been able to recommend Enhertu for use on the NHS.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	20959
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. Decisions on the availability of medicines in Scotland are a matter for the devolved administration.</p><p>The NICE published guidance in 2021 and 2023 recommending Enhertu, also known as trastuzumab deruxtecan, for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in England in line with the NICE’s recommendations.</p><p>The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and has not yet published final guidance. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process and publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:01:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1700068

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether NICE is taking steps to make Enhertu available to the National Health Service to treat incurable HER2-low secondary breast cancer.
	tabling member constituency	South Holland and The Deepings
	tabling member printed	Sir John Hayes
	uin	20865
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether Enhertu can be recommended for routine NHS funding, based on an assessment of the costs and benefits. The NICE was unfortunately unable to recommend Enhertu as a clinically and cost-effective use of NHS resources in its final draft guidance published on 5 March 2024. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process, and will publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:03:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	350 label Biography information for Sir John Hayes

1700249

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sodium Valproate: Compensation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what her planned timetable is for publishing a response to the Hughes Report on compensation for patients damaged by sodium valproate, published 7 February 2024.
	tabling member constituency	Ellesmere Port and Neston
	tabling member printed	Justin Madders
	uin	21105
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Government commissioned the Patient Safety Commissioner (PSC) to produce a report on redress for those affected by sodium valproate and pelvic mesh. We are grateful to the PSC and her team for completing this report, and our sympathies remain with those affected by sodium valproate and pelvic mesh. The Government is now carefully considering the PSC’s recommendations, and will respond substantively in due course.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 16/04/2024 13:36:40 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4418 label Biography information for Justin Madders

1700334

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department has made a recent assessment of the potential merits of using breast density assessment software at women's first breast cancer screening appointments; and if she will make an assessment of the potential impact of that technology on women's awareness of their personal risk of developing breast cancer.
	tabling member constituency	North Warwickshire
	tabling member printed	Craig Tracey
	uin	21156
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Breast Screening Risk Adaptive Imaging for Density trial is looking into the use of supplementary imaging techniques for women, within the standard breast screening programme, who are found to have radiographically dense breast tissue. The UK National Screening Committee, which advises ministers and the National Health Service in all four countries in the United Kingdom, will review this evidence when it becomes available.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 10:56:31 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4509 label Biography information for Craig Tracey

1700510

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make it her policy to allow pharmacies to sell vitamin B12 injections.
	tabling member constituency	Loughborough
	tabling member printed	Jane Hunt
	uin	21397
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>To make a medicinal product available for sale in a pharmacy without a prescription, the product must be reclassified to pharmacy only status, also known as [P] medicines, by the Medicines and Healthcare products Regulatory Agency (MHRA).</p><p>This process is triggered by an application submitted to the MHRA by a company which holds a licence for the particular product. The MHRA will consider all submitted applications, with a decision to reclassify a medicine reached following a robust evaluation of the relevant data, including evidence of the safe use and supply of the product without a prescription. The company must also demonstrate in their application that the criteria specified in relevant legislation, such as the Human Medicines Regulations 2012, have been met.</p><p>In accordance with the Human Medicines Regulations 2012, regulation 62(3), Prescription-Only Medicine status will apply where: a direct or indirect danger exists to human health, even when used correctly, if used without medical supervision; there is frequently incorrect use, which could lead to direct or indirect danger to human health; further investigation of the activity or side-effects is required; or the product is normally prescribed for parenteral administration, via injection.</p><p>Currently, United Kingdom law specifies that all products administered by injection must be subject to a prescription. The MHRA is therefore unable to reclassify the status of injections, including Vitamin B12, to [P] medicines, as this would not be consistent with the legislation.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 11:03:29 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4839 label Biography information for Jane Hunt